caroline: from bloomberg's old headquarters we talk about the european union reach its goal of vaccinating 70% of the and population. we dig into the global vaccine were lot and the politics tied to it. once the envy of the world, the u.s. is overtaken by deaths of countries -- overtaken by other

countries. we compare the see a play by doug drescher drug companies and they plan to close gaps. the u.s., eu, restrictions tied to covid. taylor: we are trying to one up each other. look at the data. look at what the science is telling us. we are tracking cases, deaths, hospitalizations, you can see in blue is the u.s.. white is the u.k.. both of them are rising. what you are not showing on the chart is the deaths and hospitalizations that have been greatly reduced given the vaccines. a lot of experts have said maybe we do not look at cases so much, even though we may see a mini surge or so. that is something we have been looking at. caroline: cases are too high to enter the eu.

the eu has a limit on how many should come in the block. we are above it. taylor: with the eu, more sections on the eu travelers -- u.s. travelers. josh what did you make of the latest headlines? we raise to get to a keith rush -- we race to get to a key threshold of vaccination. >> people are getting tired to allow the using -- loosening of rules. right now, you cannot fly directly to europe -- from europe to the u.s.. where does that leave us? this pot seems to be on the back burner. white house spread -- the white

house press secretary says the white house is considering a range of options, including forcing for nationals to be vaccinated to visit the u.s.. some countries do not even have the ability to vaccinate. the u.s. is preparing its own booster campaign, that is when to further suck up vaccine supply here. as they turn out another percentage point of people who have not decided to get the shot. 73% or so of eligible americans who've gotten the first shot. the numbers are not as high as they want them to be. there proceeding cautiously both on the continental border with canada and mexico and with international travel restrictions. these are the arguments that some doctors make for wealthy countries sharing vaccines. it is not for the goodness of their heart. with travel going back and

forth, variants spread more easily. they take off and that is what we have seen with delta. romaine: the u.s. has shipped some overseas. there is a pretty big stockpile here that would go towards booster shots. if that would be approved by the cdc and fda. is there no real manufacturing capacity where the u.s. could ship existing capacity and rely on moderna, pfizer, however to ramp up additional doses down the road? is there no she should plan for that to take place -- strategic plan for that to take place? >> they are trying to do that now. 120 million doses have been donated by the u.s. government. our doses made in the u.s. are sold directly to other countries. there are two ways the doses can

leave u.s. soil. it is a fairly big number. the donations are bigger than every other country combined. we should give a number of around 600 billion by the end of june. it is a moving target. we have talked a lot about this debate over vaccine waivers. that does not look like it is going anywhere quickly. biden's turn to have his cake and eat it too -- is trying to have his cake and eat it too. giving young adults booster shots before the data proves we need it. it it is size -- in the eyes of some health experts it will help defend himself from critics. caroline: we will talk about the vaccine inequalities. i am just -- i am interested in your takes on travel curves. some of the rates of covid are too high to allow u.s. the back

-- allow the u.s. back in certain countries are allowing u.k. to get back traveling. they are not allowing u.s. to go visiting the eu, even if you are vaccinated. jen psaki said it will tempt people to get vaccinated. even if you have a vaccine, you cannot get into the eu. >> it has been a little unclear. some countries can make an exception to this rule. i am not sure that it is baked yet, what the basis will be. these countries agree on what vaccines to recognize. will the u.s. recognize astrazeneca shots as fully vaccinated? we do not know. it is all up in the air. the politics provided domestically are that he would

rather be criticized for hoarding shots at home then for shipping them out abroad. they have not tried to walk the line at all. i get as many as they can, they added a few more to be sure, then that is when they start exporting. they have been getting pressure from g7, they have simply refused to say if and when they're going to use them. romaine: a good start to the discussion. a big discussion when we talk about the need to boost inoculation rates appeared at the biden administration's turn to encourage states to offer incentives like gift cards to get the covid-19 vaccine. you have seen this gimmick before, free doughnuts, fear, cash, anything to get people to get the vaccine. caroline: great statistics here.

taylor: we are seeing the in florida, medicaid recipients have at least one shot relative to succeed percent of eligible people statewide. the number looks more grim in louisiana. targeting areas where there is hesitancy. caroline: initially it was people wanting to get the shot, then it was like i do want to go to a game, in new york, there were tempting us if you want to watch a sports game, you have to get vaccinated. kathy had to allocate workers to get local communities to administer in more -- it more. taylor: can we talk about the irony of doughnuts. to make people more and healthy to get the vaccine to make them more healthy? caroline: everything in moderation. taylor: give me 10 donuts and i will get the vaccination. caroline: one today.

romaine: oreos? caroline: there we have it. wealthy countries across the globe rollout booster shots, many poor nations continue language -- continued to languish under the pandemic. they talk to dr. william moss at john hopkins. this is bloomberg.

romaine: today we are focused on the role of vaccines across the globe. we have a vaccine tracker that tracks the percentage of the

adult population that has been vaccinated in each country. eu at 70%. a big target that it had thought to achieve. -- hope to achieve. it is now putting europe on pace to get ahead of the united states. caroline: look at africa, no data or sub 5% of the population has been vaccinated. asia also lacking behind. -- lacking the hind -- lagging behind. we are also worried about ourselves and our own countries. how you play catch up? how do we get to herd immunity when a large population are not getting vaccines? romaine: that is a brutal tour to look at. that feeds into the debate of where some of these axis doses

-- surplus doses are going. caroline: we had the world health organization bag to not give booster shots when we have not gotten developing nations vaccinated. the executive director at the school of public health, spell out for us the risks of countries going it alone, focusing on their own populations. they are elected to do so. at the cost of people not getting vaccines in certain parts of the world. >> this global inequity is the mabel -- major problem. particularly looking at the continental -- continent of africa and the low vaccine coverage because the availability of doses. romaine: i am curious, we talk

about the inability ability -- unavailability of doses in africa and other nations in asia. we look through the lens of why the u.s. is not doing more. >> we have more than 80% of the vaccine doses going out to high paid countries. you are right, what this leads to is a circulation of the virus in countries where vaccine coverage is low. the possibility for a variants -- for new variants to emerge. we have seen reports in may, a newer variant in south africa. romaine: i am curious, when we talk about the availability of doses and various vaccines out there. we focus on the moderna, pfizer, johnson & johnson, the big drugs that came out of the u.s..

we know that there was an effort out of china, there was effort out of some other nations to develop their own vaccines. vaccines that aid some of these third world countries. has not not happened -- has that not happened? >> we see widespread distribution of vaccines from other countries. particularly china and russia. those vaccines have had different efficacy. lower efficacy than some of the vaccines we have seen manufactured in the united states. there are chinese vaccines being distributed in many african countries. it is still, we are still facing a problem with the number of doses. it is a supply problem. it is more than that.

it is getting the vaccines to the people who need them. creating the demand for the vaccines. it is a dose problem, it is also a delivery and demand problem. taylor: i know a lot of you work has been focused on international vaccine access. any takeaways from some of the domestic axis that we have -- a ccess and deploy the internationally? some not trusting or how the relationships to jesse vaccine change -- to get the vaccine change? can resolve both problems at once? >> we need to address both problems simultaneously. the biden administration has said that they can do that. there are multiple reasons for

the continued though vaccine coverage in united states. glass half-full and class have empty. -- glass half empty. the biden administration has done a great job in improving access to vaccines. it is a demand issue. here we have a number of solutions, particularly both the caret -- parents and sticks -- carrots and sticks. to get some people vaccinated. you have to think that is targeting. those incentives are targeting people who really do not see themselves as a risk of covid-19 or there is an inconvenience of getting vaccinated. these incentives may move the needle for them. for others, it is harder.

we are seeing more six. -- sticks. vaccine mandates is to get people vaccinated. caroline: i am curious about developing nations, we saw very little data, are there same issues there, or is it a question of not being able to get it from a supply side issue? is there push back from the population? >> it is not as big of a problem like we have seen in the united states. it is more of an issue of having the supply and having the delivery mechanism to get those vaccines to the people who need them. there still is misinformation and disinformation around vaccines that have created some hesitancy.

as in the united states some people still view these vaccines as extreme mental and have concerns -- as experimental and have concerns. in the low income countries, it is a problem with access. this is something that covax, led by the world health organization are really working to address. they have run into some challenges. particularly with the student of india which was supposed to be a major supplier for covax, and needing to deal with the situation in india. not able to export doses. taylor: thank you put executive director of the international vaccine axis center on the john hopkins bloomberg school of public health. vesicle is supported by the founder -- that is supported by

the parent company of this network and bloomberg philanthropies. from new york, this is bloomberg.

caroline: we are focused on the global vaccine rollout and how we are going to companies behind those efforts. moderna shows the vaccine generated it was making more than double the antibodies than other vaccines. pfizer had a days and has been the performer of the days. -- had a couple event days but has been the best performer of the year. taylor: this is on the terminal. spx l1 index, this is the member

rate returns year to date. it is moderna, a whopping 261 percent return. outperforming the s&p 500. let us see the impact on the bottom line. sam, let us take away the boost to the stock given the mrna technology. what has been the boost from the covid 19 vaccine specifically to this stock? >> covid-19 vaccine is the thing that has driven the moderna share price. it is the company, the company was years away from having the product on the market. the speed by which all of the vaccines have been able to be developed has helped them get

their product to market. what a product, over $20 billion gained this year. also what happens in the coming years and that is what the big discussion is about boosters. romaine: it has been successful we have heard from pfizer and other companies saying this is going on track to be their biggest drug ever. i am curious about the longevity of it. when we started the vaccination campaign here in the u.s. there was a lot of talk that at some point we would need a booster or need to get revaccinated altogether. this would become a cyclical thing we need to do similar to a flu shot we get every year. when you are modeling out the future revenue for some of these drugs for these companies, has that been factored in? it is going to be sticky, long-term? are you able to look out that far? >> i think the share price to a

degree is discounting. there is plenty of future revenue discounted in the share price. without doubt, for both biontech and moderna, biontech only has half a share of covid-19 vaccine sales that goes through pfizer. there is no doubt that there are some years of booster sales factored into the share price. that may not be in consensus because they are two different things. there are expectations built into the stock for booster shots. that is something investors have to be wary of when investing in the stock. caroline: thank you. and now we have breaking news. talking about transparency when

it comes to the vaccine, kathy woods fired for a new transparency etf -- filed for a new transparency etf. romaine: what is in it? caroline: she will be you tubing about it a minute. -- youtubeing about it in a minute. this is bloomberg.

and there you have it— -woah. wireless on the most reliable network nationwide. wow! -big deal! ...we get unlimited for just $30 bucks. sweet, but mine has 5g included. relax people, my wireless is crushing it. that's because you all have xfinity mobile with your internet. it's wireless so good, it keeps one upping itself. switch to xfinity mobile and save hundreds on your wireless bill. plus, save up to $400 when you purchase a new samsung phone or upgrade your existing phone. learn more at your local xfinity store today.

>> from the heart of where innovation, money, and power collide in silicon valley and beyond. this is "bloomberg technology" with emily chang. emily: coming up our, shares of zoom plunge almost 17%. it has been a lifeline for workers, students, friends, family during the pandemic.